NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Lisata Therapeutics, Inc. (LSTA) Stock Analysis

Lisata Therapeutics, Inc. (LSTA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LSTA

$1.05

+$0.01 (+0.96%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LSTA with… →

LSTA Key Statistics

As of Oct 21, 2026
Trading
Open
$1.02
Previous Close
$1.04
Day's Range
1.01–1.07
52-Week Range
0.96–5.07
Volume
45.57K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.95
Valuation
Market Cap
$11.34M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
113.44
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.64
Financials (FY)
Revenue (FY)
$170.00K−83.00%
Net Income (FY)
−$16.59M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.80M
1-Year Return
−56.25%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
300.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LSTA closed at $1.05, −56.25% over 1 year.

Lisata Therapeutics, Inc. (LSTA) has a market capitalization of $11.34M.

In fiscal 2025, LSTA reported revenue of $170.00K.

LSTA Stock Return by Calendar Year

Lisata Therapeutics, Inc. (LSTA) 10-year return: what $10,000 became

1 year
$10,000 $4,375
−56.25%
5 years
$10,000 $609
−93.91%
10 years
$10,000 $165
−98.35%

If you had invested $10,000 in Lisata Therapeutics, Inc. (LSTA) 10 years ago, at the close on October 21, 2016, it would have been worth $165 at the close on October 21, 2026: −98.35% in total, −33.68% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−43.55%
2025−37.58%
2024+9.16%
2023+7.91%
2022−79.92%
2021−41.26%
2020−43.03%
2019−29.49%
2018+1.42%
2017+24.03%
2016 (partial year)−54.50%

As of October 21, 2026.

LSTA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$170.00K−$16.59M−9,756.5%
2024$1.00M−$19.99M−1,998.5%
2023$0.00−$20.84M—
2022$0.00−$54.23M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$170.00K—−$18.21M−$16.59M−9,756.5%
2024$1.00M—−$22.41M−$19.99M−1,998.5%
2023$0.00—−$25.71M−$20.84M—
2022$0.00—−$57.60M−$54.23M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LSTA Valuation vs Biotechnology Median

Median of 608 stocks
MetricLSTABiotechnology medianvs median
P/S ratio113.4413.308.5x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lisata Therapeutics, Inc. (LSTA) is capitalised at $11.34M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 21 employees.

The 52-week range on file runs from $0.96 to $5.07. The most recent close on file for LSTA is $1.05, dated October 21, 2026. That is +$0.01 (+0.96%) against the previous close. The latest close sits 9.38% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $170.00K. That is −83.00% against the prior fiscal year, when revenue was $1.00M. The same year closed with a net loss of $16.59M. Trailing earnings per share are −1.64.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $170.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 113.44. On price-to-sales that is 8.5 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −56.25%. Measured over 10 years, that is −33.68% a year compounded. The reported beta is 0.95. Annualized volatility over the trailing 10 years is 83.79%.

Growth & Income

The record shows no dividend for LSTA.

So far in 2026 the total return is −43.55%. Across the complete calendar years on file, 2017 returned +24.03% and 2022 returned −79.92%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Lisata Therapeutics, Inc. (LSTA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lisata Therapeutics, Inc. LSTA $11.34M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Lisata Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Visit website →